

**HEPATITIS C AGENTS
PRIOR AUTHORIZATION FORM**
(form effective 1/5/2026)



Keystone First

PERFORMRxSM
Next Generation Pharmacy Benefits

Fax to PerformRxSM at **1-866-497-1387**, or to speak to a representative call **1-800-588-6767**.

PRIOR AUTHORIZATION REQUEST INFORMATION

Office contact name/phone:	
LTC facility contact/phone:	Total # pages:

BENEFICIARY INFORMATION

Beneficiary name:	Beneficiary ID #:	DOB:
-------------------	-------------------	------

PRESCRIBER INFORMATION

Prescriber name:		
Specialty:	NPI:	State license #:
Street address:		
City/state/zip:		
Phone:	Fax:	

CLINICAL INFORMATION

Requested drug #1:	
Directions:	
Qty:	<input type="checkbox"/> 8 weeks <input type="checkbox"/> 12 weeks <input type="checkbox"/> 16 weeks <input type="checkbox"/> Other:
Requested drug #2:	
Directions:	
Qty:	<input type="checkbox"/> 8 weeks <input type="checkbox"/> 12 weeks <input type="checkbox"/> 16 weeks <input type="checkbox"/> Other:
Is the beneficiary currently being treated with the requested drug(s)? <input type="checkbox"/> Yes – Therapy start date: _____ <input type="checkbox"/> No	

SUBMIT DOCUMENTATION from the medical record for all items below.

For requests for NON-PREFERRED Hepatitis C Agents direct-acting antivirals (DAAs):

- Documentation that the beneficiary tried and failed or has a contraindication or intolerance to the preferred Hepatitis C Agents. (See the Preferred Drug List for the list of preferred Hepatitis C Agents at: <https://papdl.com/preferred-drug-list>.)**
List medications tried: _____
- Cirrhosis assessment documented by a recent noninvasive test and date of testing.**
- Genotype if one of the following (check the appropriate box for the beneficiary):**
 The beneficiary is prescribed a non-pangenotypic regimen.
 The beneficiary is hepatitis C sofosbuvir-based, sofosbuvir-velpatasvir-voxilaprevir, or sofosbuvir plus glecaprevir-pibrentasvir treatment-experienced.
 The beneficiary has decompensated cirrhosis and is prescribed ledipasvir-sofosbuvir.
 The beneficiary is treatment-naïve (with cirrhosis) and prescribed sofosbuvir-velpatasvir.
- RAS (resistance-associated substitutions) testing and date of testing if one of the following (check the appropriate box for the beneficiary):**
 The beneficiary is genotype 1a and prescribed elbasvir-grazoprevir.
 The beneficiary is genotype 1a, treatment-experienced, and prescribed ledipasvir-sofosbuvir.
 The beneficiary is genotype 3, treatment-naïve (with cirrhosis) or treatment-experienced (without cirrhosis) and prescribed 12 weeks of sofosbuvir-velpatasvir.

For requests for THERAPEUTIC DUPLICATION of Hepatitis C Agents direct-acting antivirals (DAAs):
For a beneficiary taking more than 1 Hepatitis C Agents DAA product concomitantly:
 The beneficiary has a medical reason for concomitant use of the requested products that is supported by peer-reviewed medical literature or national treatment guidelines.

For requests for ALL OTHER NON-PREFERRED Hepatitis C Agents (e.g., Pegasys): Diagnosis: _____
 The beneficiary has a history of therapeutic failure of or a contraindication or an intolerance to first line therapies.
List therapies tried: _____

ATTESTATION from the prescriber for one of the items below.

Check the appropriate box for the beneficiary.
 The beneficiary is hepatitis C treatment naïve.
 The beneficiary has been treated for hepatitis C with the following treatment regimen: _____

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature:	Date:
-----------------------	-------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of any telecopy is strictly prohibited.